Dan S.

Dan S. is an Analyst at Rock Springs Capital Management LP, a Baltimore-based hedge fund that specializes in healthcare and life sciences investments. In his current role, he is responsible for conducting fundamental research and generating investment ideas across the biotechnology, pharmaceuticals, and healthcare services sectors, analyzing both public and private market opportunities. Rock Springs' portfolio and disclosures confirm a strong focus on companies within these areas, with significant holdings in firms such as Argenx, Eli Lilly, and Merus N.V.

Before joining Rock Springs Capital in 2013, Dan held the position of Research Analyst at T. Rowe Price Group for a decade, where he covered equity research in healthcare and related sectors, and prior to that, he was an Equity Analyst at Morningstar, further building his expertise in investment analysis. His career trajectory highlights over two decades of experience in public equity research, primarily focused on healthcare and biopharmaceuticals.

Although there are no public records detailing his educational background, Dan’s extensive track record at leading asset managers and his in-depth sector expertise in healthcare equities underscore his significant contributions to investment research within this specialized asset class. His analytical work has supported the allocation of capital to some of the most innovative and growth-oriented companies in the life sciences industry.